RT Journal Article SR Electronic T1 The changing treatment landscape in idiopathic pulmonary fibrosis JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 65 OP 68 DO 10.1183/09059180.00011414 VO 24 IS 135 A1 Ulrich Costabel YR 2015 UL http://err.ersjournals.com/content/24/135/65.abstract AB Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. Idiopathic pulmonary fibrosis has become a treatable disease, with two drugs now approved for this indication http://ow.ly/GhCEE